Wells Fargo Upgrades Integra Lifesciences to Overweight, Raises Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen upgraded Integra Lifesciences (IART) from Equal-Weight to Overweight and increased the price target from $40 to $49.
December 05, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Integra Lifesciences was upgraded by Wells Fargo from Equal-Weight to Overweight with a raised price target from $40 to $49.
Upgrades by analysts, especially from major financial institutions like Wells Fargo, can lead to increased investor confidence and a potential rise in stock price. The raised price target suggests a positive outlook on the company's future performance.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100